

A new Statute for ECPC

- More democratic
 - Clearer election rules
 - In line with the praxis of previous years
- Ensuring continuity
 - Creating the role Past President, we will make sure there is no disconnection between Boards
- Empowering ECPC
 - The new Scientific Committee will help us to better understand and influence cancer research
 - The new Friends of ECPC Committee will consolidate our VIPs and political contacts
- ECPC is legally more solid
 - One siege
 - Simpler financial management

Europe of Disparity in Cancer (EoDiC) ECPC's roadmap to tackle inequalities

- ECPC policy strategy, presented at ECC2015
 - Covers all the inequalities in cancer patients' journey, from early detection to survivorship
- Patient-friendly, scientifically validated recommendations to tackle inequalities in cancer care
- **EoDiC is already making a difference!**
 - ***Joint Action on Cancer Control WP5 will use it as a starting point for their policy paper on equity (2016)***
 - EoDiC's principles are at the base of the Written Declaration 30/2015, supported by ECPC and promoted by 19 MEPs



ECPC: leverages on European institutions for a solution to delays in access to cancer drugs

- **World Cancer Day 2015 declaration:** 160 MEPs supported ECPC to fight inequalities in cancer care
- **Debate in Plenary, European Parliament September 2015:** MEPs ask the Commissioner for more sustainable healthcare systems & denounced problem of access to innovative treatments
- **Written declaration 30/2015:** ECPC & 19 MEPs ask the European Parliament to take a position on sustainability of healthcare, requesting the Commission to do more to harmonise HTA process at EU level
- **Amendments to the EMA regulation 726/2004:** ECPC supported the amendments to the regulation to pave the way for the EMA to centralise the HTA assessment at the EU level and increase harmonisation

APPROVED BY ENVIRONMENTAL
EU PARLIAMENT

Amendments to the Regulation 726/2004

We are asking to:

- Overcome the unacceptable delays in access to innovative lifesaving drugs
- Cut inefficiencies, duplications (more than 50 HTA bodies exist today in Europe, working on the same set of data!)
- Produce a single pan-European relative clinical benefit assessment
- In parallel with EMA evaluation, but produced by a different body (new agency)
- Building on the work done by the Joint Action on HTA – EUnetHTA
- Better inclusion of patients in the HTA process to assess the true meaning of value

**APPROVED BY
EU PARLIAMENT (ENVI)**

4



ECPC is a true partner of research projects

- **RARECAREnet** (ended)
- **EuroCanPlatform**: sharing best standards of care (ended)
- **BenchCan**: establishing benchmarking to evaluate cancer institutes (ends in 2016)
- **eSMART**: enhanceing doctor/patient communication via mobile (ends in 2019)
- **InSup-C**: better research for palliative care (ends in 2016)
- **Mesothelioma project**: increasing cure rate in rare cancer (to start in 2016)
- **IMI 2 project**: patients perspective about new drugs (to start in 2016)
- **8 other project in review phase...**

ECPC Scientific Committee (September 2016)

**A great chance to strengthen our impact on
cancer research**